[HTML][HTML] ID: 2908 first-line nivolumab+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743
A Nowak, A Mansfield, DM Kowalski… - Journal of Thoracic …, 2020 - jto.org
Methods Adult patients with previously untreated, unresectable, histologically confirmed
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …
ID: 2908 First-Line Nivolumab+ Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
P Baas, A Scherpereel, A Nowak, N Fujimoto… - Journal of Thoracic …, 2020 - Elsevier
Methods Adult patients with previously untreated, unresectable, histologically confirmed
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …
[PDF][PDF] First-line nivolumab+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743
P Baas, A Scherpereel, AK Nowak, N Fujimoto… - vps2020.iaslc.org
• Malignant pleural mesothelioma (MPM) is a highly aggressive cancer, with a 5-year
survival rate of< 10% 1, 2• Platinum doublet chemotherapy has been the approved standard …
survival rate of< 10% 1, 2• Platinum doublet chemotherapy has been the approved standard …